Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL691 (Ethinyl estradiol component of estrostep fe, Ethinyl estradiol component of femlyv, Ethinyl estradiol component of xulane, Ethinyl estradiol component of twirla, Lynoral, Ethinylestradiolum, Ethinyl estradiol component of sprintec, 17alpha-ethinylestradiol, Ethinyl estradiol component of viorele, Etinilestradiol, Ethinyl estradiol component of lo minastrin fe, Ethinyl estradiol component of yasmin, Ethinyl estradiol component of isibloom, Ethinyl estradiol component of aranelle, Ethinyl estradiol component of volnea, Ethinyl estradiol component of femhrt, Ethinyl estradiol component of yaz, Ethinyl estradiol component of cyclessa, Ethinyl estradiol component of ortho-cept, NSC-10973, Ethinyl estradiol component of ovral, Ethinyl estradiol component of nuvaring, Ethinyl estradiol component of bekyree, Ethinyl estradiol component of loseasonique, Ethinyl estradiol component of pimtrea, Ovulen, Ethinyl estradiol component of preven, Ethinyl estradiol component of elifemme, Ethinyl estradiol component of zovia, Ethinyl estradiol component of mircette, Ethinyl estradiol component of brevicon, Ethinyl estradiol component of vienva, Ethinyl estradiol component of triphasil, Ethinyl estradiol component of orsythia, 17-ethinylestradiol, Ethinyl estradiol component of tri lo sprintec, Ethynylestradiol, Ethinyl estradiol component of seasonique, Ethinyl estradiol component of enskyce, Ethinyl estradiol component of seasonale, Ethinyl estradiol component of lo loestrin fe, Follicoral, Ethinyl estradiol component of tri-sprintec, Ethinyl estradiol component of aviane, Ethinyl estradiol component of nordette, Ethinyl estradiol component of previfem, Ethinyl estradiol component of lybrel, Ethinyl estradiol component of enpresse, Feminone, Ethinyl estradiol component of kariva, Enovid-e, Ethinyl estradiol component of altavera, Ethinyl estradiol component of beyaz, Ethinyl estradiol component of desogen, Ginestrene, Ethinyl estradiol component of taytulla, Ethinyl estradiol component of safyral, Ethinyl estradiol component of minastrin 24 fe, Ovulen-21, Ethinylestradiol, Ethinyl estradiol component of trivora, Ethinyl estradiol component of marlissa, Estinyl, Enovid, Ethinyl estradiol component of portia, Ethinyl estradiol component of kurvelo, Ethinyl estradiol component of alesse, Ethinyl estradiol component of levlite, Ethinyl estradiol component of kelnor, Ethinyl estradiol component of ortho tri-cyclen, Ethinyl estradiol component of norquest fe, Ethinyl estradiol component of levora, Ethinyl estradiol component of cryselle, Ethinyl estradiol component of tri-previfem, Ethinyl estradiol component of quartette, Ethinyl estradiol component of balcoltra, Ovulen-28, Ethinyl estradiol component of vyfemla, Ethinyl estradiol component of norinyl, Ethinyl estradiol component of annovera, Ethinyl estradiol, Ethinyl estradiol component of velivet, Ethinyl estradiol component of lessina, Etinestryl, Ethinyl estradiol component of quasense, Ethinyl estradiol component of tyblume, Ethinyl estradiol component of femcon fe, Ethinyl estradiol component of setlakin, Ethinyl estradiol component of tri-legest fe, Ethinyl estradiol component of levonest, Ethinyl estradiol component of introvale) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 4 in Guinea pig (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5017] [UniProtKB: O70528] | ||||||||
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) | B | 5.88 | pKi | 1326 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) | B | 5.1 | pIC50 | 7953 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| A2A receptor/Adenosine receptor A2a in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL251] [GtoPdb: 19] [UniProtKB: P29274] | ||||||||
| ChEMBL | DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) | B | 4.93 | pKi | 11751 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) | B | 4.68 | pIC50 | 20931 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| A3 receptor/Adenosine receptor A3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL256] [GtoPdb: 21] [UniProtKB: P0DMS8] | ||||||||
| ChEMBL | DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) | B | 4.73 | pKi | 18610 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) | B | 4.48 | pIC50 | 32925 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| aldehyde oxidase 1/Aldehyde oxidase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3257] [GtoPdb: 3186] [UniProtKB: Q06278] | ||||||||
| ChEMBL | Inhibition of human liver AOX using phthalazine as substrate incubated for 2.5 mins by HPLC-MS analysis | B | 8.3 | pIC50 | 5 | nM | IC50 | Eur J Med Chem (2020) 187: 111948-111948 [PMID:31877540] |
| Androgen receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3072] [GtoPdb: 628] [UniProtKB: P15207] | ||||||||
| ChEMBL | DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) | B | 5.96 | pKi | 1090 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881) | B | 5.09 | pIC50 | 8128.31 | nM | IC50 | J Med Chem (2005) 48: 5666-5674 [PMID:16134935] |
| ChEMBL | DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) | B | 5.79 | pIC50 | 1634 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| Estrogen receptor-α/Estrogen receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL206] [GtoPdb: 620] [UniProtKB: P03372] | ||||||||
| ChEMBL | DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) | B | 9.89 | pKi | 0.13 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | Binding affinity to ERalpha by fluorescence polarization-based competitive binding assay | B | 8.1 | pIC50 | 8.04 | nM | IC50 | J Med Chem (2010) 53: 4290-4294 [PMID:20408532] |
| ChEMBL | Binding affinity to ERalpha | B | 8.7 | pIC50 | 2 | nM | IC50 | J Med Chem (2006) 49: 3056-3059 [PMID:16722623] |
| GtoPdb | - | - | 8.7 | pIC50 | 2 | nM | IC50 | J Med Chem (2006) 49: 3056-9 [PMID:16722623] |
| ChEMBL | DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) | B | 9.35 | pIC50 | 0.45 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| ChEMBL | Antagonist activity at full length human ERalpha receptor assessed as inhibition of estradiol-induced activation incubated for 22 to 24 hrs by cell based luciferase reporter gene assay | B | 7.3 | pEC50 | >50 | nM | EC50 | Bioorg Med Chem (2020) 28: 115670-115670 [PMID:32912438] |
| ChEMBL | Agonist activity at full length human ERalpha receptor assessed as transcriptional activity incubated for 22 to 24 hrs by cell based luciferase reporter gene assay | B | 9.52 | pEC50 | 0.3 | nM | EC50 | Bioorg Med Chem (2020) 28: 115670-115670 [PMID:32912438] |
| Estrogen receptor-β/Estrogen receptor beta in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL242] [GtoPdb: 621] [UniProtKB: Q92731] | ||||||||
| ChEMBL | Binding affinity to ERbeta by fluorescence polarization-based competitive binding assay | B | 7.75 | pIC50 | 17.78 | nM | IC50 | J Med Chem (2010) 53: 4290-4294 [PMID:20408532] |
| GtoPdb | - | - | 8.09 | pIC50 | 8.1 | nM | IC50 | J Med Chem (2006) 49: 3056-9 [PMID:16722623] |
| ChEMBL | Binding affinity to ERbeta | B | 8.09 | pIC50 | 8.1 | nM | IC50 | J Med Chem (2006) 49: 3056-3059 [PMID:16722623] |
| ChEMBL | Antagonist activity at full length human ERbeta receptor assessed as inhibition of estradiol-induced activation incubated for 22 to 24 hrs by cell based luciferase reporter gene assay | B | 8 | pEC50 | >10 | nM | EC50 | Bioorg Med Chem (2020) 28: 115670-115670 [PMID:32912438] |
| ChEMBL | Displacement of fluormone from GST-tagged ERbeta receptor LBD (unknown origin) measured after 60 mins by TR-FRET competitive binding assay | B | 9.43 | pEC50 | 0.37 | nM | EC50 | Bioorg Med Chem (2020) 28: 115670-115670 [PMID:32912438] |
| ChEMBL | Agonist activity at full length human ERbeta receptor assessed as transcriptional activity incubated for 22 to 24 hrs by cell based luciferase reporter gene assay | B | 9.8 | pEC50 | 0.16 | nM | EC50 | Bioorg Med Chem (2020) 28: 115670-115670 [PMID:32912438] |
| Glucocorticoid receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2034] [GtoPdb: 625] [UniProtKB: P04150] | ||||||||
| ChEMBL | DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) | B | 6.11 | pKi | 777 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) | B | 5.77 | pIC50 | 1710 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| κ receptor/Kappa-type opioid receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL237] [GtoPdb: 318] [UniProtKB: P41145] | ||||||||
| ChEMBL | DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) | B | 4.98 | pKi | 10358 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) | B | 4.59 | pIC50 | 25894 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| Multidrug and toxin extrusion/Multidrug and toxin extrusion protein 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1743126] [GtoPdb: 1216] [UniProtKB: Q96FL8] | ||||||||
| ChEMBL | Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay | B | 4.68 | pIC50 | 21100 | nM | IC50 | J Med Chem (2013) 56: 781-795 [PMID:23241029] |
| MATE2/Multidrug and toxin extrusion protein 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1743127] [GtoPdb: 1217] [UniProtKB: Q86VL8] | ||||||||
| ChEMBL | Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay | B | 4.69 | pIC50 | 20200 | nM | IC50 | J Med Chem (2013) 56: 781-795 [PMID:23241029] |
| μ receptor/Mu-type opioid receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL233] [GtoPdb: 319] [UniProtKB: P35372] | ||||||||
| ChEMBL | DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) | B | 4.96 | pKi | 10867 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) | B | 4.57 | pIC50 | 26769 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| Constitutive androstane receptor/Nuclear receptor subfamily 1 group I member 3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5503] [GtoPdb: 607] [UniProtKB: Q14994] | ||||||||
| ChEMBL | Inverse agonist activity at GAL4 fused-human CAR-LBD transfected HEK293 cells after 24 hrs by luciferase reporter gene assay | B | 5.52 | pIC50 | 3000 | nM | IC50 | Eur J Med Chem (2016) 108: 505-528 [PMID:26717202] |
| Polyunsaturated fatty acid lipoxygenase ALOX15 in Rabbit (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4358] [UniProtKB: P12530] | ||||||||
| ChEMBL | DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) | B | 5.25 | pIC50 | 5678 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| Progesterone receptor in Bovine (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1909044] [UniProtKB: Q690N0] | ||||||||
| ChEMBL | DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) | B | 6.86 | pKi | 139 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) | B | 5.97 | pIC50 | 1067 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| Sex hormone-binding globulin in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3305] [UniProtKB: P04278] | ||||||||
| ChEMBL | Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin | B | 6.81 | pKd | 154.88 | nM | Kd | J Med Chem (2008) 51: 2047-2056 [PMID:18330978] |
| DAT/Sodium-dependent dopamine transporter in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL238] [GtoPdb: 927] [UniProtKB: Q01959] | ||||||||
| ChEMBL | DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) | B | 6.35 | pKi | 444 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) | B | 6.25 | pIC50 | 559 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| NET/Sodium-dependent noradrenaline transporter in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL222] [GtoPdb: 926] [UniProtKB: P23975] | ||||||||
| ChEMBL | DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) | B | 6.02 | pKi | 951 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) | B | 6.02 | pIC50 | 959 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| SERT/Sodium-dependent serotonin transporter in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL228] [GtoPdb: 928] [UniProtKB: P31645] | ||||||||
| ChEMBL | DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) | B | 7.54 | pKi | 29 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) | B | 7.27 | pIC50 | 54 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| Organic cation transporter 2/Solute carrier family 22 member 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1743122] [GtoPdb: 1020] [UniProtKB: O15244] | ||||||||
| ChEMBL | Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay | B | 5.66 | pIC50 | 2200 | nM | IC50 | J Med Chem (2013) 56: 781-795 [PMID:23241029] |
| Proton-coupled Amino acid Transporter 1 in Human [GtoPdb: 1161] [UniProtKB: Q7Z2H8] | ||||||||
| GtoPdb | - | - | 4.6 | pIC50 | - | - | - | J Pharm Sci (2021) 110: 354-364 [PMID:32835702] |
ChEMBL data shown on this page come from version 36:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]